{"id":2011,"date":"2026-04-22T15:40:00","date_gmt":"2026-04-22T20:40:00","guid":{"rendered":"https:\/\/global-pharma.com.co\/?p=2011"},"modified":"2026-08-04T16:28:10","modified_gmt":"2026-08-04T21:28:10","slug":"estudio-tolerabilidad-vacunas-covid-sanofi","status":"publish","type":"post","link":"https:\/\/global-pharma.com.co\/en\/estudio-tolerabilidad-vacunas-covid-sanofi\/","title":{"rendered":"Lecciones del desarrollo de vacunas contra el Covid-19: La tolerancia del paciente como estrategia comercial"},"content":{"rendered":"<p class=\"wp-block-paragraph\" id=\"ember490\">Aunque la etapa cr\u00edtica de la pandemia ha quedado atr\u00e1s, el desarrollo de vacunas y tratamientos contra el Covid-19 nos sigue dejando lecciones invaluables para la industria farmac\u00e9utica. Hoy, el mayor desaf\u00edo para la inmunizaci\u00f3n estacional no es la falta de opciones, sino la baja adherencia de los pacientes por temor a los efectos secundarios.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"ember491\">Un reciente hito en este \u00e1mbito es el estudio <strong>COMPARE<\/strong>, presentado en el Congreso Mundial de la ESCMID. Este estudio enfrent\u00f3 a dos gigantes: la vacuna basada en prote\u00ednas de Sanofi (Nuvaxovid) y la opci\u00f3n m\u00e1s reciente de ARNm de Moderna mNEXSPIKE.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"ember492\">Los resultados fueron reveladores y marcan una pauta importante para el desarrollo de futuras formulaciones:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Menos reacciones severas:<\/strong> Los s\u00edntomas sist\u00e9micos graves (como fiebre o fatiga extrema) que incapacitan a los pacientes fueron un 50% menos frecuentes con la opci\u00f3n basada en prote\u00ednas.<\/li>\n\n\n\n<li><strong>Reacciones locales reducidas:<\/strong> El dolor y la inflamaci\u00f3n en el lugar de la inyecci\u00f3n fueron un 75% menos frecuentes en comparaci\u00f3n con el ARNm.<\/li>\n\n\n\n<li><strong>Impacto en el comportamiento:<\/strong> Quienes recibieron la opci\u00f3n de Sanofi reportaron menos interrupciones en su vida diaria y mostraron casi el doble de disposici\u00f3n a repetir el mismo tipo de vacuna el a\u00f1o siguiente.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"ember494\">Como demuestra el caso de las vacunas basadas en prote\u00ednas, dise\u00f1ar productos pensando en minimizar la interrupci\u00f3n de la vida diaria del paciente es la estrategia m\u00e1s efectiva para garantizar el \u00e9xito comercial, la confianza en la marca y la adherencia a tratamientos rutinarios.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"ember495\">Para desarrollar y fabricar formulaciones estables, bien toleradas e innovadoras ya sean basadas en prote\u00ednas, extractos naturales o s\u00edntesis qu\u00edmica compleja se requiere un control absoluto sobre la calidad de los insumos. Las materias primas de alta pureza y una manipulaci\u00f3n log\u00edstica impecable son innegociables para evitar impurezas que puedan disparar reacciones adversas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"ember496\"><strong>Source:<\/strong><a href=\"https:\/\/www.enfarma.lat\/index.php\/noticias\/12574-vacuna-de-sanofi-contra-covid-19-demuestra-mejor-tolerabilidad-en-estudio-comparativo-directo\">https:\/\/www.enfarma.lat\/index.php\/noticias\/12574-vacuna-de-sanofi-contra-covid-19-demuestra-mejor-tolerabilidad-en-estudio-comparativo-directo<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>El estudio COMPARE revela c\u00f3mo la baja tasa de efectos secundarios en las vacunas basadas en prote\u00ednas optimiza la adherencia del paciente y redefine las estrategias de \u00e9xito comercial en la industria farmac\u00e9utica.<\/p>","protected":false},"author":3,"featured_media":2245,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[6],"tags":[],"class_list":["post-2011","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Desarrollo de vacunas: Tolerabilidad y \u00e9xito comercial<\/title>\n<meta name=\"description\" content=\"El estudio COMPARE revela c\u00f3mo el desarrollo de vacunas basadas en prote\u00ednas frente al ARNm redefine la adherencia del paciente y el \u00e9xito comercial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/global-pharma.com.co\/en\/estudio-tolerabilidad-vacunas-covid-sanofi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Desarrollo de vacunas: Tolerabilidad y \u00e9xito comercial\" \/>\n<meta property=\"og:description\" content=\"El estudio COMPARE revela c\u00f3mo el desarrollo de vacunas basadas en prote\u00ednas frente al ARNm redefine la adherencia del paciente y el \u00e9xito comercial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/global-pharma.com.co\/en\/estudio-tolerabilidad-vacunas-covid-sanofi\/\" \/>\n<meta property=\"og:site_name\" content=\"Global Pharma &amp; Logistic S.A.S.\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-22T20:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T21:28:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/04\/BLOG-2026-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mar\u00eda Camila Sanchez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mar\u00eda Camila Sanchez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/\"},\"author\":{\"name\":\"Mar\u00eda Camila Sanchez\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/person\\\/912625696b849a3374bc496e1df87a7c\"},\"headline\":\"Lecciones del desarrollo de vacunas contra el Covid-19: La tolerancia del paciente como estrategia comercial\",\"datePublished\":\"2026-04-22T20:40:00+00:00\",\"dateModified\":\"2026-08-04T21:28:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/BLOG-2026-1.png\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/\",\"name\":\"Desarrollo de vacunas: Tolerabilidad y \u00e9xito comercial\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/BLOG-2026-1.png\",\"datePublished\":\"2026-04-22T20:40:00+00:00\",\"dateModified\":\"2026-08-04T21:28:10+00:00\",\"description\":\"El estudio COMPARE revela c\u00f3mo el desarrollo de vacunas basadas en prote\u00ednas frente al ARNm redefine la adherencia del paciente y el \u00e9xito comercial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/BLOG-2026-1.png\",\"contentUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/BLOG-2026-1.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/estudio-tolerabilidad-vacunas-covid-sanofi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/global-pharma.com.co\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lecciones del desarrollo de vacunas contra el Covid-19: La tolerancia del paciente como estrategia comercial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#website\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/\",\"name\":\"Distribuidor de materias primas farmac\u00e9uticas en Colombia.\",\"description\":\"Principios Activos y Materias Primas en Colombia\",\"publisher\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/global-pharma.com.co\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#organization\",\"name\":\"Global Pharma & Logistic S.A.S.\",\"alternateName\":\"Global Pharma & Logistic S.A.S.\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/LOGO-COMPLETO2-02.jpg\",\"contentUrl\":\"https:\\\/\\\/global-pharma.com.co\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/LOGO-COMPLETO2-02.jpg\",\"width\":2133,\"height\":2133,\"caption\":\"Global Pharma & Logistic S.A.S.\"},\"image\":{\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/51710617\\\/admin\\\/dashboard\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/global-pharma.com.co\\\/#\\\/schema\\\/person\\\/912625696b849a3374bc496e1df87a7c\",\"name\":\"Mar\u00eda Camila Sanchez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g\",\"caption\":\"Mar\u00eda Camila Sanchez\"},\"url\":\"https:\\\/\\\/global-pharma.com.co\\\/en\\\/author\\\/maria-sanchez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Desarrollo de vacunas: Tolerabilidad y \u00e9xito comercial","description":"El estudio COMPARE revela c\u00f3mo el desarrollo de vacunas basadas en prote\u00ednas frente al ARNm redefine la adherencia del paciente y el \u00e9xito comercial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/global-pharma.com.co\/en\/estudio-tolerabilidad-vacunas-covid-sanofi\/","og_locale":"en_US","og_type":"article","og_title":"Desarrollo de vacunas: Tolerabilidad y \u00e9xito comercial","og_description":"El estudio COMPARE revela c\u00f3mo el desarrollo de vacunas basadas en prote\u00ednas frente al ARNm redefine la adherencia del paciente y el \u00e9xito comercial.","og_url":"https:\/\/global-pharma.com.co\/en\/estudio-tolerabilidad-vacunas-covid-sanofi\/","og_site_name":"Global Pharma &amp; Logistic S.A.S.","article_published_time":"2026-04-22T20:40:00+00:00","article_modified_time":"2026-08-04T21:28:10+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/04\/BLOG-2026-1.png","type":"image\/png"}],"author":"Mar\u00eda Camila Sanchez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mar\u00eda Camila Sanchez","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#article","isPartOf":{"@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/"},"author":{"name":"Mar\u00eda Camila Sanchez","@id":"https:\/\/global-pharma.com.co\/#\/schema\/person\/912625696b849a3374bc496e1df87a7c"},"headline":"Lecciones del desarrollo de vacunas contra el Covid-19: La tolerancia del paciente como estrategia comercial","datePublished":"2026-04-22T20:40:00+00:00","dateModified":"2026-08-04T21:28:10+00:00","mainEntityOfPage":{"@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/global-pharma.com.co\/#organization"},"image":{"@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#primaryimage"},"thumbnailUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/04\/BLOG-2026-1.png","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/","url":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/","name":"Desarrollo de vacunas: Tolerabilidad y \u00e9xito comercial","isPartOf":{"@id":"https:\/\/global-pharma.com.co\/#website"},"primaryImageOfPage":{"@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#primaryimage"},"image":{"@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#primaryimage"},"thumbnailUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/04\/BLOG-2026-1.png","datePublished":"2026-04-22T20:40:00+00:00","dateModified":"2026-08-04T21:28:10+00:00","description":"El estudio COMPARE revela c\u00f3mo el desarrollo de vacunas basadas en prote\u00ednas frente al ARNm redefine la adherencia del paciente y el \u00e9xito comercial.","breadcrumb":{"@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#primaryimage","url":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/04\/BLOG-2026-1.png","contentUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2026\/04\/BLOG-2026-1.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/global-pharma.com.co\/estudio-tolerabilidad-vacunas-covid-sanofi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/global-pharma.com.co\/"},{"@type":"ListItem","position":2,"name":"Lecciones del desarrollo de vacunas contra el Covid-19: La tolerancia del paciente como estrategia comercial"}]},{"@type":"WebSite","@id":"https:\/\/global-pharma.com.co\/#website","url":"https:\/\/global-pharma.com.co\/","name":"Distribuidor de materias primas farmac\u00e9uticas en Colombia.","description":"Principios Activos y Materias Primas en Colombia","publisher":{"@id":"https:\/\/global-pharma.com.co\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/global-pharma.com.co\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/global-pharma.com.co\/#organization","name":"Global Pharma & Logistic S.A.S.","alternateName":"Global Pharma & Logistic S.A.S.","url":"https:\/\/global-pharma.com.co\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/global-pharma.com.co\/#\/schema\/logo\/image\/","url":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2025\/08\/LOGO-COMPLETO2-02.jpg","contentUrl":"https:\/\/global-pharma.com.co\/wp-content\/uploads\/2025\/08\/LOGO-COMPLETO2-02.jpg","width":2133,"height":2133,"caption":"Global Pharma & Logistic S.A.S."},"image":{"@id":"https:\/\/global-pharma.com.co\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/51710617\/admin\/dashboard\/"]},{"@type":"Person","@id":"https:\/\/global-pharma.com.co\/#\/schema\/person\/912625696b849a3374bc496e1df87a7c","name":"Mar\u00eda Camila Sanchez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0329561f75938cb23698a3fea3fb2b239761b6609e52728bd3aef6667c8eecb3?s=96&d=mm&r=g","caption":"Mar\u00eda Camila Sanchez"},"url":"https:\/\/global-pharma.com.co\/en\/author\/maria-sanchez\/"}]}},"_links":{"self":[{"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/posts\/2011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/comments?post=2011"}],"version-history":[{"count":4,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/posts\/2011\/revisions"}],"predecessor-version":[{"id":2153,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/posts\/2011\/revisions\/2153"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/media\/2245"}],"wp:attachment":[{"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/media?parent=2011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/categories?post=2011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/global-pharma.com.co\/en\/wp-json\/wp\/v2\/tags?post=2011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}